Glucagon-like peptide-1 receptor agonists and major limb events in adults with type 2 diabetes and peripheral artery disease: a systematic review and meta-analysis of RCTs and cohort studies
Pooled result · Major limb eventsResult — go to the resultRelative risk 0.73 95% CI 0.65–0.82Authors' conclusion
Among adults with T2D and PAD, treatment with GLP-1RAs was associated with a lower risk of major limb events.
Study context
- Population
- Adults with T2D and peripheral artery disease (PAD)12 studies (2 RCTs, 10 matched cohorts)
- Participants
- 418,282 adults
- Comparison
- GLP-1 RA use vs placebo, active comparators or non-use
- Outcome
- Composite of major limb events, as defined by the investigators of the original studies
Methodological detailssubgroup analyses, leave-one-out sensitivity analyses, meta-regression, Literature search from inception to 31 March 2026
- Subgroup analyses
- Leave-one-out sensitivity analyses
- Meta-regression
- Literature search from inception to 31 March 2026
Pooled result
Major limb events
Relative risk
0.73
95% CI 0.65–0.82
GLP-1RAsvs Placebo, active comparators or non-use
RR 0.73 (95% CI 0.65–0.82)
As reported in the abstract
- Significantly lower risk of major limb events
- 27%
Further pooled results
Lower extremity amputation (LEA)
- LEA, RR
- 0.76 (95% CI 0.66-0.87)
Revascularization
- Revascularization, RR
- 0.81 (95% CI 0.77-0.86)
Gangrene
- Gangrene, RR
- 0.80 (95% CI 0.77-0.85)
Major adverse cardiovascular events (MACE)
- MACE, RR
- 0.76 (95% CI 0.63-0.90)
All-cause mortality
- All-cause mortality, RR
- 0.67 (95% CI 0.61-0.73)
Original publication
Glucagon-like peptide-1 receptor agonists and major limb events in adults with type 2 diabetes and peripheral artery disease: a systematic review and meta-analysis of RCTs and cohort studies. Cardiovasc Diabetol. Published 6 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →